Final data from monarcHER suggest the utility of triple therapy over standard of care chemotherapy
Numerically improved overall survival was shown with abemaciclib plus trastuzumab and fulvestrant in patients with advanced breast cancer
Phase I studies provide further data on the use of T-cell based therapies in solid tumours
Different approaches are explored, showing good efficacy and mixed tolerability, but further studies are needed to assess their feasibility
Mixed results from the use of selective ER degraders and modulators in advanced breast cancer
These results highlight the need to better investigate the mechanisms of action, define the optimal timing of administration and identify predictive biomarkers
Building a lasting foundation for precision oncology
While local and regional initiatives address some major barriers, global efforts are needed to make molecularly guided options accessible to all patients.
The CXCR2 antagonist AZD5069 plus enzalutamide is shown to be active in mCRPC
In a phase I/II study, the combination treatment was tolerable in men who had progressed on one novel anti-androgen therapy
The ESMO Global Study on Access to Cancer Medicines shows stark global inequalities
The availability and affordability of a broad range of prescription cancer medicines have been analysed
Survival benefit in two trials of first-line immunotherapy in advanced hepatocellular carcinoma
Encouraging efficacy data with anti-PD1 antibody in combination or as monotherapy
Positive clinical results for immunotherapy in metastatic/recurrent cervical cancer
Results from two studies shows promise for combination immunotherapy in a population with a high unmet need for new treatments
Can telehealth be a genuine replacement for face-to-face healthcare?
In the post-COVID-19 era, there is a need to evaluate the quality, safety and effectiveness of telehealth to deliver cancer care says ESMO Keynote Lecturer Dr Deborah Schrag
Overall survival data further support sacituzumab govitecan in HR+/HER2– metastatic breast cancer
Findings from the TROPiCS-02 trial show an overall survival benefit of sacituzumab govitecan in heavily pre-treated patients but raise questions about its optimal clinical implementation